v3.25.2
Segment Reporting - Schedule of Reconciliation of Segment Net Loss (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2025
Jun. 30, 2024
Segment Reporting Information [Line Items]            
License and collaboration revenue $ 48   $ 24,116   $ 48 $ 24,116
Research and development expense (8,773)   (5,348)   (15,406) (14,011)
General and administrative expense (4,699)   (5,122)   (9,513) (9,092)
Other income, net 580   1,231   1,809 5,201
Income tax expense (55)   (30)   (109) (60)
Reconciliation of loss (income):            
Net (loss) income (12,899) $ (10,272) 14,847 $ (8,693) (23,171) 6,154
Treatment Of Respiratory Diseases Segment            
Reconciliation of loss (income):            
Net (loss) income (12,899)   14,847   (23,171) 6,154
Operating Segment | Treatment Of Respiratory Diseases Segment            
Segment Reporting Information [Line Items]            
License and collaboration revenue 48   24,116   48 24,116
Research and development expense (8,773)   (5,348)   (15,406) (14,011)
General and administrative expense (4,699)   (5,122)   (9,513) (9,092)
Other income, net 580   1,231   1,809 5,201
Income tax expense (55)   (30)   (109) (60)
Reconciliation of loss (income):            
Net (loss) income (12,899)   14,847   (23,171) 6,154
Adjustments and reconciling items | Treatment Of Respiratory Diseases Segment            
Reconciliation of loss (income):            
Net (loss) income $ 0   $ 0   $ 0 $ 0